APOBEC deaminases as cellular antiviral factors: A novel natural host defense mechanism

Medical Science Monitor

Volumn 12, Issue 5, 2006, Pages

  Franca, Raffaella ^a   Spadari, Silvio ^a   Maga, Giovanni ^a  

^a CNR   (Italy)

Author keywords

APOBECs; Human immunodeficiency virus (HIV); Vif antiviral natural defense

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3C; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3D; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3E; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CULLIN; CYTIDINE DEAMINASE; CYTOSINE; ELONGIN B; ELONGIN C; PROTEASOME INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; URACIL; URACIL DNA GLYCOSYLTRANSFERASE; VIF PROTEIN; VIRUS DNA; VIRUS RNA;

ANTIVIRAL ACTIVITY; CATALYSIS; DEAMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE; MACROPHAGE; MULTIDRUG RESISTANCE; MUTAGENESIS; NONHUMAN; REVIEW; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANIMALS; ANTI-HIV AGENTS; CYTIDINE DEAMINASE; GENE PRODUCTS, VIF; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEOSIDE DEAMINASES; REPRESSOR PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; VIRUS REPLICATION;

EID: 33646468134     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Conticello SG, Harris RS, Neuberger MS: The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol, 2003; 13: 2009-13
2. Saunders HL, Magor BG: Cloning and expression of the AID gene in the channel catfish. Dev Comp Immunol, 2004; 28: 657-63
3. Harris RS, Liddament MT: Retroviral restriction by APOBEC proteins. Nat Rev Immunol, 2004; 4: 868-77
4. Jarmuz A, Chester A, Bayliss J et al: An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics, 2002; 79: 285-96
5. Honjo T, Muramatsu M, Fagarasan S: AID: how does it aid antibody diversity? Immunity, 2004; 20: 659-68
6. Neuberger MS, Harris RS, Di Noia J, Petersen-Mahrt SK: Immunity through DNA deamination. Trends Biochem Sci, 2003; 28: 305-12
7. Anant S, Mukhopadhyay D, Sankaranand V et al: ARCD-1, an apobec-1-related cytidine deaminase, exerts a dominant negative effect on C to U RNA editing. Am J Physiol Cell Physiol, 2001; 281: C1904-16
8. Liao W, Hong SH, Chan BH et al: APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine deaminase supergene family. Biochem Biophys Res Commun, 1999; 260: 398-404
9. Mikl MC, Watt IN, Lu M et al: Mice deficient in APOBEC2 and APOBEC3. Mol Cell Biol, 2005; 25: 7270-27
10. Lau PP, Villanueva H, Kobayashi K et al: A DnaJ protein, apobec-1-binding protein-2, modulates apolipoprotein B mRNA editing. J Biol Chem, 2001; 276: 46445-52
11. Anant S, MacGinnitie AJ, Davidson NO: Apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding protein. J Biol Chem, 1995; 270: 14762-67
12. Yang Y, Sowden MP, Smith HC: Induction of cytidine to uridine editing on cytoplasmic apolipoprotein B mRNA by overexpressing APOBEC-1. J Biol Chem, 2000; 275: 22663-69
13. Turelli P, Trono D: Editing at the crossroad of innate and adaptive immunity. Science, 2005; 307: 1061-65
14. Waterston RH, Lindblad-Toh K, Birney E et al: Initial sequencing and comparative analysis of the mouse genome. Nature, 2002; 420: 520-62
15. Rogozin IB, Basu MK, Jordan IK et al: APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle, 2005; 4: 1281-85
16. Kan NC, Franchini G, Wong-Staal F et al: Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera. Science, 1986; 231: 1553-55
17. Lee TH, Coligan JE, Allan JS et al: A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science, 1986; 231: 1546-49
18. Rabson AB, Daugherty DF, Venkatesan S et al: Transcription of novel open reading frames of AIDS retrovirus during infection of lymphocytes. Science, 1985; 229: 1388-90
19. Sodroski J, Goh WC, Rosen C et al: Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science, 1986; 231: 1549-53
20. Fisher AG, Ensoli B, Ivanoff L et al: The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science, 1987; 237: 888-93
21. Oberste MS, Gonda MA: Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes, 1992; 6: 95-102
22. Chakrabarti L, Guyader M, Alizon M et al: Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature, 1987; 328: 543-47
23. Guyader M, Emerman M, Sonigo P et al: Genome organization and transactivation of the human immunodeficiency virus type 2. Nature, 1987; 326: 662-69
24. Guy B, Geist M, Dott K et al: A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein. J Virol, 1991; 65: 1325-31
25. Saltarelli M, Querat G, Konings DA et al: Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus. Virology, 1990; 179: 347-64
26. Sonigo P, Alizon M, Staskus K et al: Nucleotide sequence of the visna lentivirus: relationship to the AIDS virus. Cell, 1985; 42: 369-82
27. Talbott RL, Sparger EE, Lovelace KM et al: Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci USA, 1989; 86: 5743-47
28. Madani N, Kabat D: An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol, 1998; 72: 10251-55
29. Simon JH, Gaddis NC, Fouchier RA, Malim MH: Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med, 1998; 4: 1397-400
30. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 2002; 418: 646-50
31. von Schwedler U, Song J, Aiken C, Trono D: Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol, 1993; 67: 4945-55
32. Courcoul M, Patience C, Rey F et al: Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J Virol, 1995; 69: 2068-74
33. Goncalves J, Korin Y, Zack J, Gabuzda D: Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol, 1996; 70: 8701-9
34. Simon JH, Malim MH: The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol, 1996; 70: 5297-305
35. Dettenhofer M, Cen S, Carlson BA et al: Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol, 2000; 74: 8938-45
36. Gabuzda DH, Lawrence K, Langhoff E et al: Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol, 1992; 66: 6489-95
37. Sova P, Volsky DJ: Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol, 1993; 67: 6322-26
38. Ochsenbauer C, Wilk T, Bosch V: Analysis of vif-defective human immunodeficiency virus type 1 (HIV-1) virions synthesized in 'non-permissive' T lymphoid cells stably infected with selectable HIV-1. J Gen Virol, 1997; 78: 627-35
39. Gaddis NC, Chertova E, Sheehy AM et al: Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol, 2003; 77: 5810-20
40. Mangeat B, Turelli P, Caron G et al: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature, 2003;424: 99-103. Epub 2003 May 28
41. Zhang H, Yang B, Pomerantz RJ et al: The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature, 2003; 424: 94-98
42. Harris RS, Bishop KN, Sheehy AM et al: DNA deamination mediates innate immunity to retroviral infection. Cell, 2003; 113: 803-9
43. Lecossier D, Bouchonnet F, Clavel F, Hance AJ: Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science, 2003; 300: 1112
44. Beale RC, Petersen-Mahrt SK, Watt IN et al: Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol, 2004; 337: 585-96
45. Yu Q, Konig R, Pillai S et al: Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol, 2004; 11: 435-42
46. Klarmann GJ, Chen X, North TW, Preston BD: Incorporation of uracil into minus strand DNA affects the specificity of plus strand synthesis initiation during lentiviral reverse transcription. J Biol Chem, 2003; 278: 7902-9
47. Stopak K, de Noronha C, Yonemoto W, Greene WC: HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell, 2003; 12: 591-601
48. Kao S, Khan MA, Miyagi E et al: The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol, 2003; 77: 11398-407
49. Mariani R, Chen D, Schrofelbauer B et al: Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell, 2003; 114: 21-31
50. Marin M, Rose KM, Kozak SL, Kabat D: HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med, 2003; 9: 1398-403
51. Sheehy AM, Gaddis NC, Malim MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med, 2003; 9: 1404-7
52. Liu B, Yu X, Luo K et al: Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol, 2004; 78: 2072-81
53. Yu X, Yu Y, Liu B et al: Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science, 2003; 302: 1056-60
54. Mehle A, Strack B, Ancuta P et al: Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem, 2004; 279: 7792-98
55. Wichroski MJ, Ichiyama K, Rana TM: Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J Biol Chem, 2005; 280: 8387-96
56. Kile BT, Schulman BA, Alexander WS et al: The SOCS box: a tale of destruction and degradation. Trends Biochem Sci, 2002; 27: 235-41
57. Kobayashi M, Takaori-Kondo A, Miyauchi Y et al: Ubiquitination of APOBEC3G by an HIV-1 Vif-cullin5-elonginB-elonginC complex is essential for Vif function. J Biol Chem, 2005; 21: 21
58. Bishop KN, Holmes RK, Sheehy AM et al: Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol, 2004; 14: 1392-96
59. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR: A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. Embo J, 2004; 23: 2451-58
60. Zheng YH, Irwin D, Kurosu T et al: Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol, 2004; 78: 6073-76
61. Liddament MT, Brown WL, Schumacher AJ, Harris RS: APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol, 2004; 14: 1385-91
62. Yu Q, Chen D, Konig R et al: APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem, 2004; 279: 53379-86
63. Simon V, Zennou V, Murray D et al: Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification. PLoS Pathog, 2005; 1: e6
64. Shindo K, Takaori-Kondo A, Kobayashi M et al: The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J Biol Chem, 2003; 278: 44412-16
65. Newman EN, Holmes RK, Craig HM et al: Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol, 2005; 15: 166-70
66. Navarro F, Bollman B, Chen H et al: Complementary function of the two catalytic domains of APOBEC3G. Virology, 2005; 333: 374-86
67. Langlois MA, Beale RC, Conticello SG, Neuberger MS: Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res, 2005; 33: 1913-23
68. Bishop KN, Holmes RK, Sheehy AM, Malim MH: APOBEC-mediated editing of viral RNA. Science, 2004; 305: 645
69. Rosler C, Kock J, Kann M et al: APOBEC-mediated interference with hepadnavirus production. Hepatology, 2005; 42: 301-9
70. Lochelt M, Romen F, Bastone P et al: The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc Natl Acad Sci USA, 2005; 102: 7982-87
71. Sasada A, Takaori-Kondo A, Shirakawa K et al: APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology, 2005; 2: 32
72. Rosler C, Kock J, Malim MH et al: Comment on "Inhibition of hepatitis B virus replication by APOBEC3G". Science, 2004; 305: 1403
73. Turelli P, Mangeat B, Jost S et al: Inhibition of hepatitis B virus replication by APOBEC3G. Science, 2004; 303: 1829
74. Yang QE: Eradication of HIV in infected patients: some potential approaches. Med Sci Monit, 2004; 10(7): RA155-RA165
75. Berkhout B, de Ronde A: APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. Aids, 2004; 18: 1861-63
76. Mangeat B, Turelli P, Liao S, Trono D: A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem, 2004; 279: 14481-83
77. Schrofelbauer B, Chen D, Landau NR: A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA, 2004; 101: 3927-32
78. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR: A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA, 2004; 101: 3770-74